Clinical Data AZ is three for three with COPD hope tozorakimab PharmaphorumAstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.Clinical DataRespiratoryRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trump backs psychedelics for mental health in new executive orderNext: The Omnichannel Gap: Building the CRM of the Future for Patient Services Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
